

BRITISH SOCIETY OF TOXICOLOGICAL PATHOLOGY

The 38th Annual Scientific Meeting of the British Society of Toxicological Pathology



Preclinical translatability and pathology of cell-based therapies

Wednesday 15th – Thursday 16th November 2023

Evotec, Verona, Italy

Approved by the Royal Society of Biology for purposes of CPD, this event may be counted as 33 CPD credits.
Approximately 11.5 hours of educational activity will be recorded on Attendance Certificates.

PROGRAMME

Wednesday 15th November 2023	
08.30 - 09.15	REGISTRATION
09.15 - 09.30	WELCOME AND INTRODUCTION BY THE PRESIDENT OF THE BSTP - Catherine Ross
Session 1: Advancing Cell-Based Therapies (Chair: Catherine Ross)	
09.30 - 10.15	Cell and gene therapy: Current advances and new perspectives for cell genetic engineering Prof Luigi Naldini (San Raffaele Telethon Institute for Gene Therapy, Italy)
10.15 - 11.00	Designing safer gene transfer vectors and stem cell manufacturing processes Prof Fulvio Mavilio (Orchard Therapeutics, UK)
11.00 - 11.30	REFRESHMENT BREAK AND POSTER SESSION
Session 2: Cell-based Therapies: Therapeutic Opportunities I (Chair: Aleks Zalewska)	
11.30 - 12.15	Use of differentiated pluripotent stem cells as powerful and complex ATMP on the treatment of monogenic diseases Dr Ana Bejanariu (Sanofi, France)
12.15 - 13.00	Harnessing the power of haematopoietic stem cells: From bench to bedside Prof Bernhard Genter (San Raffaele Telethon Institute for Gene T Therapy, Italy) 
13.00 - 13.15	Deciphex Sponsor Talk 
13.15 - 14.15	LUNCH
14.15 - 15.00	Neuronal stem cell transplantation in patients with progressive multiple sclerosis Prof Gianvito Martino (IRCCS San Raffaele Scientific Institute, Italy) 
Session 3: Modifying Lymphocytes (Chair: Peter Clements)	
15.00 - 15.20	T2EVOLVE: A European initiative to speed up the availability of CAR-T therapy in Europe Dr Carmen Sanges (UKW, Germany) 
15.20 - 15.40	Profiling CAR-T cell performances in humanized mice Dr Monica Casucci (IRCCS San Raffaele Scientific Institute, Italy)
15.40 - 16.00	Predicting safety and efficacy of engineered T cells using an ex vivo human model Dr Emmanuel Donnadieu (INSERM, France)
16.00 - 16.30	REFRESHMENT BREAK
16.30 - 17.00	Tregs: Opportunities & challenges Dr Jan Klapwijk (Cornelis Consulting, UK)
17.00 - 17.30	Case studies: Challenges during preclinical assessment of 2 cell-based therapies Dr Deon Hildebrand (GSK, UK)
17.30 onwards	Canapé Reception & transfer to city centre

V: 08/11/2023

You are advised that the programme timings, lecture title and speakers may be subject to change without notice

Registered Charity No: 1043793

BRITISH SOCIETY OF TOXICOLOGICAL PATHOLOGY

The 38th Annual Scientific Meeting of the British Society of Toxicological Pathology



Preclinical translatability and pathology of cell-based therapies

Wednesday 15th – Thursday 16th November 2023

Evotec, Verona, Italy

Approved by the Royal Society of Biology for purposes of CPD, this event may be counted as 33 CPD credits.

Approximately 11.5 hours of educational activity will be recorded on Attendance Certificates.

PROGRAMME

Thursday 16th November 2023	
08.15 - 08.55	REGISTRATION
08.55 - 09.00	INTRODUCTION TO DAY 2 BY THE PRESIDENT OF THE BSTP - Catherine Ross
Session 4: Best Practices in Preclinical Development of Cell-based Therapy Products (Chair: Jan Klapwijk)	
09.00 - 09.45	 ESTP Science Award 2023 <i>Role of pathology in regenerative solid organ cell therapy strategies</i> Dr Magnus Söderberg (AstraZeneca, Sweden)
09.45 - 10.30	 IATP Maronpot Guest Lecture Award Recipient <i>The Pathologist's role in the Preclinical Strategy for Cell Based Medicinal Products</i> Dr Alys Bradley (Charles River Laboratories, UK)
10.30 - 11.00	REFRESHMENT BREAK AND POSTER SESSION
11.00 - 11.45	<i>Pathology of graft-host interactions</i> Dr Patrizia Cristofori (San Raffaele Telethon Institute for Gene Therapy, Italy)
Session 5: Cell-based Therapies: Therapeutic Opportunities II (Chair: Peter Clements)	
11.45 - 12.10	<i>Preclinical strategy & challenges of iPSC-based cell therapeutics</i> Dr Matthias Austin (Evotec, Germany)
12.10 - 12.35	<i>Generating Preclinical Safety Data for a First-in-Class Regenerative Cell Therapy for Hearing Loss: A collaboration between Academia, Biotech and a Contract Research Organization</i> Dr Leila Abbas (RINRI Therapeutics, UK)
12.35 - 12.50	<i>Reliable Safety Testing for the Rapidly Growing Gene Therapy Cohort of Treatments is Becoming More Urgent</i> Robert Spencer (TestAVec) 
12.50 - 13.50	LUNCH
Session 6: Regulatory Corner – an interactive case with the MHRA (Chair: Jan Klapwijk and Patrizia Cristofori)	
13.50 - 14.50	<i>Scientific advice from MHRA - an example - Project X</i>  Dr James McBlane (MHRA, UK)
Session 7: Combined Medical Device & Cell-based Therapies (Chair: Gio Pellegrini)	
14.50 - 15.35	<i>Challenges and opportunities in preclinical development of combined cell-based medical device products</i> Dr Pramila Singh (Charles River Laboratories, UK)
15.35 - 16.05	REFRESHMENT BREAK AND POSTER SESSION
16.05 - 16.30	<i>Cell therapy combined with a medical device to treat type 1 diabetes</i> Dr Michela Gabaldo (Evotec, Italy)
16.30 - 16.45	CONCLUDING REMARKS BY THE PRESIDENT OF THE BSTP – Catherine Ross

V: 08/11/2023

You are advised that the programme timings, lecture title and speakers may be subject to change without notice

BRITISH SOCIETY OF TOXICOLOGICAL PATHOLOGY

The 38th Annual Scientific Meeting of the British Society of Toxicological Pathology



Preclinical translatability and pathology of cell-based therapies

Wednesday 15th – Thursday 16th November 2023

Evotec, Verona, Italy

Approved by the Royal Society of Biology for purposes of CPD, this event may be counted as 33 CPD credits.
Approximately 11.5 hours of educational activity will be recorded on Attendance Certificates.

PROGRAMME

V: 08/11/2023

You are advised that the programme timings, lecture title and speakers may be subject to change without notice

Registered Charity No: 1043793